--- title: "The benefits of investments to combat HIV, tuberculosis, and malaria for primary healthcare from 2000 to 2023: An economic modeling analysis" id: "plos-medicine-9-the-benefits-of-investments-to-combat-hiv-tuberculosis-and-malaria-for-primary-healthcare-from-2000-to-2023-an-economic-modeling-analysis" canonical_url: "https://medichelpline.com/clinical-feed/plos-medicine-9-the-benefits-of-investments-to-combat-hiv-tuberculosis-and-malaria-for-primary-healthcare-from-2000-to-2023-an-economic-modeling-analysis" content_type: "clinical_feed_article" specialty: "Research Highlights" source_name: "PLOS Medicine" source_url: "https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005036" published_at: "2026-04-08T14:00:00.000Z" evidence_level: "Journal Feed" license: "CC-BY-NC-4.0 / Informational Use" --- # The benefits of investments to combat HIV, tuberculosis, and malaria for primary healthcare from 2000 to 2023: An economic modeling analysis ## Provenance & Clinical Metadata - **Canonical URL:** https://medichelpline.com/clinical-feed/plos-medicine-9-the-benefits-of-investments-to-combat-hiv-tuberculosis-and-malaria-for-primary-healthcare-from-2000-to-2023-an-economic-modeling-analysis - **Specialty:** [Research Highlights](https://medichelpline.com/clinical-feed/research-highlights.md) - **Primary Source:** PLOS Medicine - **Source URL:** [Original Journal Publication](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005036) - **Published At:** 2026-04-08T14:00:00.000Z - **Evidence Rating:** Journal Feed ## Executive GIST (TL;DR) by Jiaying Stephanie Su, John Stover, Carel Pretorius, Peter Winskill, Sedona Sweeney, Timothy B. Hallett, Nicolas A. Menzies Background Global investments to combat HIV, tuberculosis, and malaria (HTM) have delivered substantial health gains and may have reduced the burden placed by these diseases on the routine health system. We estimated the reduction in primary healthcare (PHC) utilization resulting from the scale-up of HTM services over 2000–2023 in 108 low- and middle-income countries. Methods and findings For each disease, we applied established mathematical models to quantify PHC utilization (outpatient visits and inpatient bed-days provided outside of HTM programs) by individuals with symptomatic HIV, tuberculosis, or malaria unable to access HTM-specific services. For each country, we estimated averted PHC utilization by comparing a scenario describing the actual scale-up of HTM services to a counterfactual scenario holding HTM service coverage constant at year 2000 levels. We applied published unit costs to estimate the averted costs resulting from reduced PHC utilization. Over 2000–2023, scale-up of HTM services averted an estimated 6.9 (95% uncertainty interval (UI) [4.4, 10.5]) billion outpatient PHC visits and 3.9 (95% UI [2.5, 5.9]) billion inpatient bed-days, representing US$135 (95% UI [71, 250]) billion in averted costs. These reductions were greatest in sub-Saharan Africa and East Asia and Pacific regions. Across study countries, these reductions represented a median of 4.4% of hospital bed capacity and 1.6% of government health spending in 2023. These percentages were 22.9% and 5.1%, respectively, for low-income countries. Our analysis did not consider changes in PHC services beyond utilization. Also, several inputs were missing in some countries, with missing values estimated using regression imputation. Conclusions Over recent decades, sustained investments in HTM services in high-burden settings have averted substantial PHC utilization and associated costs. These benefits should be considered when assessing investment impact. ## Clinical Analysis & Structured Key Points by Jiaying Stephanie Su, John Stover, Carel Pretorius, Peter Winskill, Sedona Sweeney, Timothy B. Hallett, Nicolas A. Menzies Background Global investments to combat HIV, tuberculosis, and malaria (HTM) have delivered substantial health gains and may have reduced the burden placed by these diseases on the routine health system. We estimated the reduction in primary healthcare (PHC) utilization resulting from the scale-up of HTM services over 2000–2023 in 108 low- and middle-income countries. Methods and findings For each disease, we applied established mathematical models to quantify PHC utilization (outpatient visits and inpatient bed-days provided outside of HTM programs) by individuals with symptomatic HIV, tuberculosis, or malaria unable to access HTM-specific services. For each country, we estimated averted PHC utilization by comparing a scenario describing the actual scale-up of HTM services to a counterfactual scenario holding HTM service coverage constant at year 2000 levels. We applied published unit costs to estimate the averted costs resulting from reduced PHC utilization. Over 2000–2023, scale-up of HTM services averted an estimated 6.9 (95% uncertainty interval (UI) [4.4, 10.5]) billion outpatient PHC visits and 3.9 (95% UI [2.5, 5.9]) billion inpatient bed-days, representing US$135 (95% UI [71, 250]) billion in averted costs. These reductions were greatest in sub-Saharan Africa and East Asia and Pacific regions. Across study countries, these reductions represented a median of 4.4% of hospital bed capacity and 1.6% of government health spending in 2023. These percentages were 22.9% and 5.1%, respectively, for low-income countries. Our analysis did not consider changes in PHC services beyond utilization. Also, several inputs were missing in some countries, with missing values estimated using regression imputation. Conclusions Over recent decades, sustained investments in HTM services in high-burden settings have averted substantial PHC utilization and associated costs. These benefits should be considered when assessing investment impact. ## Related Clinical Research - [Beyond isolated cough events: AI-based tuberculosis screening through temporal analysis of cough sounds](https://medichelpline.com/clinical-feed/medrxiv-12-beyond-isolated-cough-events-ai-based-tuberculosis-screening-through-temporal.md) - [Predicting radiological severity of pulmonary tuberculosis in children: an assessment of the WHO-criteria and novel prediction scores on an individual participant dataset](https://medichelpline.com/clinical-feed/medrxiv-2-predicting-radiological-severity-of-pulmonary-tuberculosis-in-children-an.md) - [Comparative impacts and cost-effectiveness of tuberculosis systematic screening strategies in prisons in Brazil, Colombia, and Peru: A mathematical modeling study](https://medichelpline.com/clinical-feed/plos-medicine-22-comparative-impacts-and-cost-effectiveness-of-tuberculosis-systematic-screening.md) - [Economic evidence of health technology innovations for the diagnosis of extrapulmonary TB in resource-limited settings: a scoping review protocol](https://medichelpline.com/clinical-feed/bmj-open-15-economic-evidence-of-health-technology-innovations-for-the-diagnosis-of-extrapulmonary-tb-in-resource-limited-settings-a-scoping-review-protocol.md) - [Impact of a Person-Centered Care Intervention on HIV Treatment Reengagement in Zambia](https://medichelpline.com/clinical-feed/plos-medicine-2-effect-of-a-person-centered-care-intervention-on-return-and-sustained.md) ## Navigation - [← Back to Research Highlights Feed](https://medichelpline.com/clinical-feed/research-highlights.md) - [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md) ## Medical & Regulatory Disclaimer > [!CAUTION] > MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations. > Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.